国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司 1 关于上海医药集团股份有限公司 2025 年第二次临时股东大会的法律意见书 致：上海医药集团股份有限公司 国浩律师（上海）事务所（以下简称"本所"），接受上海医药集团股份有 限公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第二次临 时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）以及《上 海医药集团股份有限公司章程》（以下简称"《公司章程》"）的规定出具本法 律意见书。 本所依据本法律意见书出具日之前已经发生或存在的事实及中国（为出具本 法律意见书之目的，本法律意见书中的"中国"仅指中国大陆地区，不包括香港 特别行政区和澳门特别行政区及台湾地区）现行法律、法规及规范性文件发表法 律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师应得到上海医药如下保证：其已提供了本所律师 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-113 上海医药集团股份有限公司 2025年第二次临时股东大会决议公告 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 12 月 9 日 (二)股东大会召开的地点：中国上海市黄浦区太仓路 200 号上海医药大厦二楼会 议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 903 | | --- | --- | | 其中：A 股股东人数 | 902 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 2,252,731,543 | | 其中：A 股股东持有股份总数 | 1,838,474,580 | | 境外上市外资股股东持有股份总数（H 股） | 414,256,963 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 60.7474 | | 份总数的比例（%） | | | --- | --- | | 其中：A 股股东持股占股份总数的比例（%） | 49.5765 ...

Group 1 - The core point of the announcement is that Shanghai Pharmaceuticals Holding Co., Ltd. has successfully included its drug, Amisulpride Orally Disintegrating Tablets, in the National Medical Insurance Catalog, effective from January 1, 2026 [1][4]. - The drug is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, and is used for the treatment of adult schizophrenia [1][4]. - The drug's registration details include a specification of 50mg and 0.2g, with approval numbers H20250041 and H20250042 [1]. Group 2 - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [2]. - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is approximately RMB 168.41 million [3].

【最新百强医药批发和零售企业发布：国药集团和大参林位居榜首】2025年12月8日，商务部官网发布 了《2024年药品流通行业运行统计分析报告》。2024年前10大医药批发企业分别是：国药集团、上海医 药、华润医药、九州通、重庆医药—中国医药联合体、广州医药、南京医药、华东医药、英特集团、海 王生物。 2024年前10大医药零售企业分别是：大参林、益丰药房、国大药房、老百姓、一心堂、同仁堂、健之 佳、漱玉平民、好药师、河南张仲景大药房。 2024年，全国药品流通市场销售规模略有增长。统计显示，全国七大类医药商品销售总额为29470亿 元，扣除不可比因素同比增长0.6%。其中，药品零售市场销售额为6500亿元，扣除不可比因素同比增 长1.3%；药品批发市场销售额为22970亿元，扣除不可比因素同比增长0.5%。 截至2024年年底，全国共有《药品经营许可证》持证企业70.54万家。其中批发企业1.51万家，同比增加 0.03万家；零售连锁企业6607家，同比减少118家；下辖门店39万家，同比增加0.44万家；零售单体药店 29.37万家，同比增加1.23万家。零售药店总数68.37万家，同比增加1.67万家。 ...

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shenyang Pharmaceutical Co., Ltd., successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are an improved formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched Amisulpride orally disintegrating tablets [1] - Shanghai Shenyang Pharmaceutical Co., Ltd. became the marketing authorization holder for Amisulpride orally disintegrating tablets after receiving approval from the National Medical Products Administration in October 2025 [1]

Core Viewpoint - Shanghai Pharmaceuticals has successfully included its amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective January 1, 2026, which is expected to enhance market share and competitiveness [1] Group 1: Company Information - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has obtained the marketing authorization for amisulpride orally disintegrating tablets [1] - The amisulpride orally disintegrating tablets are a modified formulation of amisulpride tablets originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched amisulpride orally disintegrating tablets [1] Group 2: Market Impact - The inclusion of amisulpride orally disintegrating tablets in the National Medical Insurance Directory is expected to expand the product's market share and improve its competitive position [1] - According to the IQVIA database, the hospital procurement amount for amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1] - The successful negotiation for inclusion in the insurance directory will provide valuable experience for the company in promoting other products [1]

Core Viewpoint - Shanghai Pharmaceuticals has successfully included its amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective January 1, 2026, which is expected to enhance market share and competitiveness [1] Group 1: Company Information - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has obtained the listing rights for amisulpride orally disintegrating tablets [1] - The amisulpride orally disintegrating tablets are a modified formulation of the amisulpride tablets launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched amisulpride orally disintegrating tablets [1] Group 2: Market Impact - The inclusion of amisulpride orally disintegrating tablets in the National Medical Insurance Directory is expected to expand the product's market share and improve its competitive position [1] - According to the IQVIA database, the hospital procurement amount for amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1] - The successful negotiation for inclusion in the insurance directory will provide valuable experience for the company in promoting other products [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its drug, Amisulpride Orally Disintegrating Tablets, has been successfully included in the National Medical Insurance Catalog, effective from January 1, 2026, following negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1: Drug Information - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., became the marketing authorization holder for Amisulpride Orally Disintegrating Tablets after approval from the National Medical Products Administration in October 2025 [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] Group 2: Market Data - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於氨磺必利口崩片通過國家醫保談判並成功納入國家 醫保目錄的公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 12 月 9 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 关于氨磺必利口 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its product, Amisulpride Orally Disintegrating Tablets, has been successfully included in the National Medical Insurance Directory, effective January 1, 2026, following negotiations with the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The National Medical Insurance Directory for 2025 was published on December 7, 2025, by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] - The Amisulpride Orally Disintegrating Tablets are a modified formulation of the original Amisulpride Tablets launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., became the marketing authorization holder for Amisulpride Orally Disintegrating Tablets after approval from the National Medical Products Administration in October 2025 [1]